Gilead Skids After Coronavirus Drug Reportedly Fails A Critical TestInvestors Business Daily • 04/23/20
Gilead stock plummets after disappointing COVID-19 drug trial results published by accidentFast Company • 04/23/20
Gilead says draft of coronavirus treatment results contain 'inappropriate characterization' and are 'inconclusive'CNBC • 04/23/20
Gilead stock tumbles after Stat report on weak data in remdesivir trial in ChinaMarket Watch • 04/23/20
New data on Gilead's remdesivir, released by accident, show no benefit for coronavirus patients. Company still sees reason for hopeCNBC • 04/23/20
Dow pares some gains after report says Gilead's remesivir shows disappointing resultsMarket Watch • 04/23/20
Gilead Sciences Races to Manufacture Remdesivir, but Chemistry Has Speed LimitsThe Motley Fool • 04/22/20
A Speculator's View On Gilead Sciences And Its Hopes To Treat The Coronavirus PandemicSeeking Alpha • 04/20/20